RCI
BCYC

Ridgeback Capital Investments’s Bicycle Therapeutics BCYC Stock Holding History

Ridgeback Capital Investments’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-844,235
Closed -$15.3M – 2
2023
Q4 		$15.3M Buy
+844,235
New +$14M 62.17% 1
2023
Q1 		– Sell
-2,264,801
Closed -$67M – 2
2022
Q4 		$67M Buy
+2,264,801
New +$60.8M 80.44% 1
2022
Q1 		– Sell
-2,164,801
Closed -$132M – 2
2021
Q4 		$132M Buy
+2,164,801
New +$119M 71.77% 1

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Ridgeback Capital Investments's BCYC Position: Q1 2024 in Review

Ridgeback Capital Investments sold out of Bicycle Therapeutics (BCYC) in Q1 2024, closing a stake of 844,235 shares — an estimated $15.3M sold.

Ridgeback Capital Investments first reported a position in BCYC in Q4 2021 and held it in 3 quarters. The position peaked at $132M in Q4 2021. 95 funds tracked by Wall St. Rank hold BCYC as of Q1 2024.

  • Ridgeback Capital Investments reported no remaining Bicycle Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Ridgeback Capital Investments sold 844,235 Bicycle Therapeutics shares in Q1 2024, an estimated $15.3M.
  • Ridgeback Capital Investments first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 3 quarters.
  • Ridgeback Capital Investments's Bicycle Therapeutics position peaked at $132M in Q4 2021.
  • 95 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2024.

Based on Ridgeback Capital Investments's 13F filing for Q1 2024.